Auspex Pharmaceuticals
2001
FOUNDED
M&A
STATUS
31-40
EMPLOYEES
M&A
LATEST DEAL TYPE
$3.5B
LATEST DEAL AMOUNT
Description
Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. It focuses on the development of drugs for the treatment of involuntary movement disorders, respiratory disease and inflammation.
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Parent Company
Teva Pharmaceutical Industries
Primary Office
- 3366 North Torrey Pines Court
- Suite 225
- San Diego, CA 92037
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Auspex Pharmaceuticals’s full profile, request a free trial.
Auspex Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Merger/Acquisition | 05-May-2015 | $3.5B | 00000 | 00.00 | Completed | Clinical Trials - Phase 3 |
| 15. 2PO | 30-Jan-2015 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 | |
| 14. 2PO | 11-Jul-2014 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 13. IPO | 05-Feb-2014 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 12. Loan | 08-Jan-2014 | 0000 | 00000 | Completed | Clinical Trials - Phase 3 | |
| 11. Later Stage VC (Series E) | 20-Dec-2013 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 10. Later Stage VC (Series D) | 06-Sep-2013 | 0000 | 0000 | 000.00 | Completed | Clinical Trials - Phase 3 |
| 9. Loan | 11-Mar-2013 | 0000 | Completed | Clinical Trials - Phase 3 | ||
| 8. Later Stage VC | 09-Nov-2012 | $19M | $70M | Completed | Clinical Trials - Phase 3 | |
| 7. Later Stage VC | 28-Dec-2011 | $3M | $51M | Completed | Generating Revenue |
Auspex Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series D | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A5 | 00,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A4 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A3 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A2 | 610,294 | $0.000100 | 8% | $1.7 | $1.7 | 1x | $1.7 | 0.87% |
| Series A1 | 613,500 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 0.88% |
Auspex Pharmaceuticals Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| BioMed Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Costa Verde Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Foresite Capital Management | Growth/Expansion | Minority | 000 0000 | 000000 0 | ||
| Panorama Capital | Venture Capital | Minority | 000 0000 | 000000 0 |
Auspex Pharmaceuticals Executive Team (11)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Pratik Shah Ph.D | President, Chief Executive Officer & Board Member | ||
| Andreas Sommer Ph.D | Chief Scientific Officer |
9 Former Executives
You’re viewing 2 of 11 executives. Get the full list »Auspex Pharmaceuticals Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Gerald Proehl | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 1 of 7 board members. Get the full list »